(Bioheart, Inc. has since changed their name to US Stemcell, Inc.)

Bioheart Announces Successful Grand Opening of Facility in South Africa

Sunrise, FL – September 24, 2014

Bioheart, Inc. (BHRT.OB), a biotechnology company  focused  on  the  discovery,  development  and,  subject  to  United  States  regulatory approval,  commercialization  of  autologous  cell  therapies  for  the  treatment  of  degenerative diseases, announces a successful grand opening of the laboratory and clinic in South Africa.

The new facility named The South African Stem Cell Institute, immediately began treating patients. Last week a total of 12 patients underwent autologous cell therapies for the treatment of various conditions.

All of  the  patients  received  an  in clinic  treatment  as  well  as  cell  culture  expansion  and cryopreservation.  The  patients’  cells  were  multiplied  and  will  be  preserved  in  sub-zero temperatures for future treatments as required.

Kristin Comella, Bioheart’s Chief Science Officer, who attended the grand opening, said, “The facilities in South Africa are top notch and mirror FDA facilities that we have in the U.S. Bioheart has provided the necessary training and expertise to the staff at the South African Stem Cell Institute.

The team  in  South  Africa  is  highly  trained  and  prepared  to  provide  excellent  regenerative medicine care to patients in South Africa.”

Bioheart’s  new  joint  venture  has  established  an  important  relationship  within  the South  African  government.  The Ministry of Health will be adopting Bioheart protocols making them the standard of care for patients in South Africa.

Bioheart will assume 49% ownership of the new entity. Dr. Walter Bell and the team at the South African Stem Cell Institute will offer these therapies to the more than 51 million people living in South Africa.

 

 

Bioheart Announces Successful Grand Opening of Facility in South Africa

Sunrise, FL – September 16, 2014

Bioheart, Inc. (BHRT.OB), a biotechnology company focused on the discovery, development and, subject to regulatory approval, commercialization  of  autologous  cell  therapies  for  the  treatment  of  degenerative diseases, announces the grand opening of the laboratory and clinic in South Africa.

Bioheart previously announced the joint venture with Dr. Walter Bell last quarter. The facilities in South Africa opening this week will be able to provide cell therapies in the clinic as well as cell culture expansion and cryopreservation to local patients. Bioheart can multiply and preserve an individual’s cells in sub-zero temperatures for future treatments as required.

Kristin  Comella,  Bioheart’s  Chief  Science  Officer,  who  is  attending  the  grand opening  said: “We  are  so  thrilled  to  open  this  facility  in  just  over  3  months.    There  are millions of  patients  in  South  Africa  and  neighboring  countries  who  can  benefit  from regenerative medicine.”

Bioheart’s  partnership  will  establish  a  critical  relationship  with  the  South  African government  and  the  joint  venture  will  work  closely  with  the  Ministry  of  Health  to  make Bioheart protocols part of the standard of care for patients in South Africa and neighboring countries.  Bioheart  has  provided  the  necessary  training  and  expertise  to  transfer Bioheart therapies to the new facility.